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Controversy surrounds setting a lower limit of
normal testosterone. There is also no generally
accepted lower limits of normal testosterone level in
ageing males. Patients with serum total testosterone
levels below 8 nmol/L (230 ng/dL) will usually ben-
efit from testosterone treatment, those with testos-
terone level above 12 nmol/L (350 ng/dL) not
require substitution, but ìgrey zoneî between 8 and
12 nmol/L still exists. It was demonstrated that
demographic differences in testosterone level within
population of aging males exist (1ñ3). In healthy
adult men, about 44% of the circulating testosterone
bound to sex-hormone binding protein (SHBG) is
tightly bound and thus biologically inactive, 50% is
nonspecifically bound to albumin, and 3.5% is
bound to cortisol-binding globulin. Only 2ñ3% of
testosterone is unbound (free) and thus bioactive (4).
Concentrations of SHBG are related to variables
such as diet, body mass index (BMI), insulin con-
centrations and age (5). Diet low in protein in elder-
ly men may lead to elevated SHBG levels and
decreased testosterone availability and activity.
SHBG level influences bioactive testosterone level
especially when serum albumin is low (6). SHBG
level is not related to total calories, nor fat (animal
or vegetable), nor carbohydrate intake. The decrease
in bioactive testosterone can result in declines in
sexual function, muscle strength, red cell count, and
contribute to the loss of bone density (7). The meas-
urement of free (bioavailable) testosterone should be
considered when total testosterone can not confirm
the symptoms related to hypogonadism, particularly
in obese men (1). Men with low total testosterone
and low SHBG have an increased risk of diabetes
dependent of obesity (8). Bioavailable (free) testos-
terone positively correlated with muscle strength
and bone mineral density, and is known to better
reflect clinical symptoms of late onset hypogo-
nadism than total testosterone (9), but it is difficult
to found the firm threshold values for bioactive
testosterone, depending on the method used and
being not generally available (5, 10, 11). Difficulties
can be found when one would classify the clinical
syndrome related to late onset hypogonadism. It is
due to the high prevalence of hypogonadal symp-
toms in the ageing male population and the non-spe-
cific nature of these symptoms. Late onset hypogo-
nadism often coexists with obesity and metabolic
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syndrome (12, 13). The overall prevalence of late
onset hypogonadism varies from 6ñ9% in men aged
40ñ70 years and rises to 15ñ30% in diabetic and
obese men (14, 15). Late onset hypogonadism will
be in the near future a very often treated syndrome
due to the fact that obesity is common from child-
hood (16). 
Testosterone secretion is disturbed in obese males
Testosterone secretion is regulated by compli-
cated feedback loops. Many factors influence on
testosterone secretion. The most important are
gonadotropin release hormone (GnRH) and luteiniz-
ing hormone (LH), which are involved in main neg-
ative feedback loop. Follicule stimulating hormone
(FSH), dihydrotestosterone (DHT), estradiol and
prolactin seems to control testosterone level as well.
LH secretion is under negative feedback control by
gonadal steroids, both testosterone and estradiol.
The androgens slow the frequency of LH pulsate
release (16). LH pulse modulation remains undis-
turbed in severely obese men but LH amplitude is
significantly attenuated compared to non-obese
individuals. Decreased LH levels and LH pulse
amplitude were observed in the massively obese
men with BMI > 40 kg/m2 (17). There are also such
factors like: inhibin, activin, adrenocorticotropic
hormone (ACTH), leptin, neuropeptide Y, semen
production, androgen receptor expression and func-
tion, liver function and serum protein production,
which can influence testosterone secretion (12, 13,
18). FSH acts in the control of spermatogenesis fol-
lowing its binding to the FSH receptor in the basal
aspect of the plasma membrane of Sertoli cells. FSH
secretion is modulated by activin and inhibin (18).
Obesity is associated with increased plasma levels
of leptin, the obese gene product secreted from
adipocytes. Circulating leptin correlates with total
and free testosterone independently of SHBG, LH
and estradiol, so it seems that leptin is the best hor-
monal predictor of lower androgen levels in obese
men. Leptin receptors are present in testicular tissue
and leptin may play a role in reduced androgen lev-
els in obese men (19). 
Obesity leads to metabolic syndrome, which is
common in ageing males and often coexists with
late onset hypogonadism. Obesity is associated with
a reduction in serum total testosterone and SHBG
levels (20). Men who were obese, whether measured
by BMI or central obesity (waist-hip ratio or waist
circumference) had a greater decline of free and
total testosterone and SHBG, compared to men who
were never classified as obese (21). Visceral adipose
tissue correlate independently with free (bioactive)
testosterone (22) and is associated with decreased
basal cortisol secretion and increased cortisol
response to exogenous adrenocorticotropin stimula-
tion, which may contribute to higher insulin levels
and decreased SHBG levels (23).
Metabolic syndrome is connected with non-
alcoholic fatty liver disease, which can be a conse-
quence of diet (24). Patients with more severe liver
disease have lower testosterone and PSA levels than
patients less affected (25). Male reproductive sys-
tem is impaired early in liver dysfunction (26). It
seems that, the way from obesity to hypogonadism
is logical and empirically proven. Is the reverse rela-
tionship possible?
Does testosterone influence obesity?
Several questions are arising, but the most
important is: Can simply testosterone replacement
therapy rebuilt the balance of its regulation feedback
system? It has to be emphasized that we intent to
treat mostly men with functional Leydig cells.
Complex multiple alternations of the testosterone
secretion in older men are linked to modifiable risk
factors like obesity, smoking and life style (13, 27).
The second important question is: Can testosterone
be really responsible for all symptoms and disor-
ders, which occurred during ageing in men? In other
words, can testosterone be used to treat obesity, and
obesity related disorders like diabetes type 2, hyper-
cholesterolemia, hypertension, ischemic heart dis-
ease, and cardiac failure and finally metabolic syn-
drome? It is worth to point out that obesity is regard-
ed as a trigger factor leading to many mentioned
above disorders including metabolic syndrome. On
the other hand, it was shown that testosterone treat-
ment can lead to an increase lean mass and decrease
obesity in hypogonadic ageing males (12, 13, 27,
28). It is very interesting, how the obesity in ageing
males should be interpreted? Does obesity result
from a low serum testosterone level or does obesity
exert an influence on testosterone level? The answer
to this question is crucial for possible treatment
decision. It seems that metabolic syndrome is not a
consequence of low testosterone level, but low plas-
ma testosterone concentration is only a coincidence
with visceral obesity. One can suspect that metabol-
ic syndrome can decrease testosterone level in age-
ing males. Some data show that lower levels of total
testosterone and SHBG are predictive of the devel-
opment of the metabolic syndrome, particularly in
men with BMI < 25 kg/m2 (29). Others suggest that
the metabolic syndrome is an independent factor of
hypogonadism in middle-aged men (30) and relative
androgen deficiency appears to be a marker for,
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rather than a cause of, metabolic syndrome in older
men (31). This phenomenon and presented relation-
ships remain unresolved (32). 
How should we treat an obese men with hypogo-
nadal symptoms?
Elevated intake of fat and carbohydrates and
particularly fructose, which is common sweetener in
beverages cause metabolic syndrome (24).
Consumption of fructose-sweetened but not glu-
cose-sweetened beverages increases de novo lipid
synthesis, promotes dyslipidemia, impairs insulin
sensitivity, and increases visceral adiposity (33, 34).
Replacing sugar-sweetened beverages intake with
water is associated with reductions in total calories
and weight loss (35, 36). 
Obesity is an important risk factor for many
common diseases including cardiovascular disease,
type 2 diabetes, cancer and erectile dysfunction (16,
37). It has to be emphasized that 100 kcal/day reduc-
tion would eliminate 71.2 mln cases of obesity in
US, while 5 g/day reduction of fat would eliminate
3.9 mln cases of high cholesterol in US (38). The
highest rates of obesity and type 2 diabetes are
observed among people with low level of tested
parameters, who used energy-dense food as the best
way to provide daily calories. Obesity is the toxic
consequence of economic insecurity and a failing
economic environment, but not the effect of low
testosterone (39). Obesity and obesity-related disor-
ders, are epidemic in Western countries, where
cheap energy-dense food is available, but not in real-
ly poor countries (40).
The link between physical activity and testos-
terone level can be easily shown. Anabolic hor-
mones such as testosterone and growth hormones
are elevated after exercise. Exercise leads to signifi-
cant increases in testosterone and growth hormones
in women and men (41, 42). A large number of tri-
als have demonstrated a positive effect of testos-
terone treatment on bone mineral density and bone
architecture, because it is an anabolic hormone,
which takes part in ìbody buildingî, but there is lack
of data to prove that testosterone treatment in ageing
males reduces fractures (12, 43ñ46).
The androgen receptor and several enzymes
involved in androgen metabolism are also expressed
in adipose tissue. It is true that dihydrotestosterone
(DHT) inhibits adipocyte differentiation in subcuta-
neous and intraabdominal (omental) adipocyte in
humans. 5α-DHT inactivation was detected in
abdominal adipose tissue in men (47). Testosterone
replacement therapy (parenteral testosterone unde-
canoate) generates physiological levels of DHT
(48). On the other hand, it has to be emphasized that
the regional depot difference in androgen inactiva-
tion rates could be a consequence of obesity. It was
found significantly higher 5α-DHT inactivation
rates in mature adipocytes compared with
preadipocytes in subcutaneous adipose tissue (47,
49). Serum DHT levels do not change markedly
with advancing age, but some studies suggest that
DHT treatment may be a useful alternative for hor-
mone replacement therapy in older men (50, 51).
Based on a large amount of evidence it can be easi-
ly proved that testosterone level decreasing is an
effect of improper life style, diet and lack of physi-
cal activity, which can lead to metabolic syndrome.
It is worth to ask; Do we really need a testosterone
replacement therapy in obese ageing males, who
present a metabolic syndrome and low testosterone
level? Most consistent effects of treatment have
been on body composition. It was suggested that
androgen administration to elderly men should be
reserved for the minority of elderly men who have
both clear clinical symptoms of hypogonadism and
frankly low serum testosterone levels (20). It was
proved that therapy including the both elements, i.e.,
body mass reduction and testosterone treatment can
lead to success in obese ageing males with hypogo-
nadism, but this fact did not exclude that body mass
reduction alone would exert similar effect (52). One
could speculate that preventing late onset hypogo-
nadism through healthy life style and diet is a much
better way than testosterone augmentation in obese
ageing males. We think that this point of view
deserves future studies. 
Conclusions 
High fat and fructose consumption is responsi-
ble for development of obesity and metabolic syn-
drome, which are characterized by low testosterone
level. Obesity and lack of physical activity can neg-
atively influence the testosterone level. Low testos-
terone level should be regarded as an effect of obe-
sity, but reverse relationship has not been proved
yet. 
We hypothesized that management of late-
onset hypogonadism symptoms has to be treated
with a change of a life style and prevented with a
program focused on healthy nutrition and physical
activity in youth and elderly, as well. The question
related to rational indications for testosterone
replacement therapy in obese males seems to be still
actual. 
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